Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Does ERG Expression Predict Docetaxel Benefit in Prostate Cancer?

Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy (ADT), according to... Read More

Addressing Physical, Cognitive Effects of ADT in Prostate Cancer Patients

At this year’s American Society of Clinical Oncology (ASCO) Annual meeting, Alicia K. Morgans, MD, assistant professor of medicine in... Read More

Prostate Cancer Molecular Subtyping Groups Tumors by Prognosis, Response

Molecular subtyping of prostate cancer into three categories—luminal A, luminal B, and basal—identifies differences in prognosis and response to treatment,... Read More

Urinary RNA Testing Could Avoid Unnecessary Prostate Biopsies

Combined urinary testing for PCA3 and TMPRSS2:ERG (T2:ERG) RNA can help avoid unnecessary biopsies while maintaining ability to detect aggressive... Read More

AUA: Prostate Cancer Surveillance Yields Good Results in Younger Patients

Active surveillance can yield excellent results in carefully selected younger men with prostate cancer, according to a new study. A... Read More

Custirsen Does Not Improve Overall Survival in mCRPC

The addition of custirsen to docetaxel and prednisone failed to improve overall survival among patients with metastatic castration-resistant prostate cancer... Read More

Testosterone Replacement Linked to Lower Rates of Aggressive Prostate Cancer

Men who receive testosterone replacement therapy (TRT) had an increased rate of favorable-risk prostate cancer compared to those who did... Read More

Liquid Biopsy Shows Promise in Advanced Prostate Cancer

“Liquid biopsy” analyses of circulating tumor DNA (ctDNA) from blood samples potentially reveal prognostic information about metastatic castration-resistant prostate cancer... Read More

Photodynamic Therapy Can Preserve Tissue in Low-Risk Prostate Cancer

Vascular-targeted photodynamic therapy with padeliporfin was significantly better than active surveillance over a 2-year period in men with low-risk localized... Read More

No Prostate Cancer Mortality Benefit With PSA Screening

Long-term follow-up of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) confirmed earlier results showing no reduction in... Read More

1 2 3 4